newsfilter
← Latest News
GlobeNewswire·

AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Company on track to report three-month interim study results, including visual acuity, visual sensitivity, mobility and safety data, in Q2 2022 Company providing further updated guidance on other milestones GAINESVILLE, Fla. and CAMBRIDGE, Mass.